Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125986271 | 12598627 | 1 | I | 20140705 | 20140723 | 20160726 | 20160726 | EXP | DE-BFARM-14215345 | DE-MYLANLABS-2014M1000811 | MYLAN | 0.00 | Y | 0.00000 | 20160726 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125986271 | 12598627 | 1 | PS | ATORVASTATIN | ATORVASTATIN | 1 | 40 MG, QD | U | 91226 | 40 | MG | QD | |||||||
| 125986271 | 12598627 | 2 | SS | ATORVASTATIN | ATORVASTATIN | 1 | 120 MG, UNK | U | 91226 | 120 | MG | ||||||||
| 125986271 | 12598627 | 3 | SS | ATORVASTATIN | ATORVASTATIN | 1 | 40 MG, QD | U | 91226 | 40 | MG | QD | |||||||
| 125986271 | 12598627 | 4 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 11775 MG, UNK | U | 0 | 11775 | MG | ||||||||
| 125986271 | 12598627 | 5 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 75 MG, QD | U | 0 | 75 | MG | QD | |||||||
| 125986271 | 12598627 | 6 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 75 MG, QD | U | 0 | 75 | MG | QD | |||||||
| 125986271 | 12598627 | 7 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | U | 0 | |||||||||||
| 125986271 | 12598627 | 8 | C | CARMEN /00740901/ | 2 | 10 MG, QD | U | 0 | 10 | MG | QD | ||||||||
| 125986271 | 12598627 | 9 | C | TORASEMIDE | TORSEMIDE | 1 | 20 MG, QD | U | 0 | 20 | MG | QD | |||||||
| 125986271 | 12598627 | 10 | C | SOTALOL. | SOTALOL | 1 | 160 MG, QD | U | 0 | 160 | MG | QD | |||||||
| 125986271 | 12598627 | 11 | C | SOTALOL. | SOTALOL | 1 | 80 MG, BID | U | 0 | 80 | MG | BID | |||||||
| 125986271 | 12598627 | 12 | C | SOTALOL. | SOTALOL | 1 | U | 0 | |||||||||||
| 125986271 | 12598627 | 13 | C | BENZBROMARON | 2 | 100 MG, QD | U | 0 | 100 | MG | QD | ||||||||
| 125986271 | 12598627 | 14 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 3000 MG, QD | U | 0 | 3000 | MG | QD | |||||||
| 125986271 | 12598627 | 15 | C | MARCUMAR | PHENPROCOUMON | 1 | 3 MG, QD | U | 0 | 3 | MG | QD | |||||||
| 125986271 | 12598627 | 16 | C | EUTHYROX | LEVOTHYROXINE SODIUM | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125986271 | 12598627 | 1 | Lipid metabolism disorder |
| 125986271 | 12598627 | 7 | Stent placement |
| 125986271 | 12598627 | 8 | Hypertension |
| 125986271 | 12598627 | 9 | Oedema peripheral |
| 125986271 | 12598627 | 12 | Arrhythmia |
| 125986271 | 12598627 | 16 | Thyroid operation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125986271 | 12598627 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125986271 | 12598627 | Abnormal loss of weight | |
| 125986271 | 12598627 | Asthenia | |
| 125986271 | 12598627 | Blood glucose increased | |
| 125986271 | 12598627 | Decreased appetite | |
| 125986271 | 12598627 | Intestinal obstruction | |
| 125986271 | 12598627 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125986271 | 12598627 | 1 | 20140703 | 0 | ||
| 125986271 | 12598627 | 5 | 20140130 | 0 |